Captor Therapeutics Spolka Akcyjna Stock Warsaw S.E.
Stocks
CTXA
PLCPTRT00063
Biotechnology & Medical Research
| Market Cap | 465M 126M 108M 101M 92.28M 173M 12.05B 177M 1.19B 6.04B 473M 462M 19.99B | P/E 2026 * |
23.8x | P/E 2027 * | -282x |
|---|---|---|---|---|---|
| Enterprise Value | 393M 106M 90.98M 84.89M 77.89M 146M 10.17B 149M 1.01B 5.1B 399M 390M 16.87B | EV / Sales 2026 * |
6.92x | EV / Sales 2027 * | 8.16x |
| Free-Float |
70.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +1.98% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 41 | 31/05/2025 | |
| Director of Finance/CFO | - | 01/02/2025 | |
Andrew Saunders
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 30/06/2022 | |
| Director/Board Member | 74 | 30/06/2022 | |
| Director/Board Member | - | 30/06/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.98% | +24.19% | - | - | 126M | |
| -0.24% | +3.84% | +3.03% | +24.32% | 51.22B | |
| -1.36% | +4.82% | +485.55% | +614.84% | 45.38B | |
| -2.04% | +3.69% | +19.34% | +91.23% | 41.97B | |
| +2.72% | +6.02% | +33.33% | +19.66% | 42.15B | |
| 0.00% | -3.91% | +18.49% | +47.98% | 31.95B | |
| -1.85% | +3.48% | - | - | 16.73B | |
| +0.72% | +5.27% | +31.55% | +145.37% | 17.1B | |
| -0.58% | +2.78% | +6.47% | +34.67% | 14.76B | |
| +0.50% | +3.62% | +82.64% | +46.53% | 13.91B | |
| Average | -0.02% | +3.24% | +85.05% | +128.07% | 30.58B | |
| Weighted average by Cap. | -0.24% | +3.18% | +103.63% | +150.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 56.7M 15.35M 13.14M 12.26M 11.25M 21.14M 1.47B 21.56M 145M 736M 57.63M 56.37M 2.44B | 48.5M 13.13M 11.24M 10.49M 9.62M 18.08M 1.26B 18.44M 124M 630M 49.29M 48.22M 2.08B |
| Net income | -3M -812K -695K -649K -595K -1.12M -77.7M -1.14M -7.7M -38.94M -3.05M -2.98M -129M | -1.5M -406K -348K -324K -298K -559K -38.85M -570K -3.85M -19.47M -1.52M -1.49M -64.46M |
| Net Debt | -72.5M -19.62M -16.8M -15.68M -14.39M -27.03M -1.88B -27.56M -186M -941M -73.69M -72.08M -3.12B | -69.5M -18.81M -16.11M -15.03M -13.79M -25.91M -1.8B -26.42M -178M -902M -70.64M -69.1M -2.99B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
